The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma
Conclusions:
Increased expression of FGFR1 and FRS2α was associated with decreased PFS among patients with metastatic RCC treated with sorafenib. The results suggest that FGF pathway activation may impact intrinsic resistance to VEGF receptor inhibition.
Source: BMC Cancer - Category: Cancer & Oncology Authors: Thai HoXian-De LiuYanqing HuangCarla WarnekeMarcella JohnsonAnh HoangPheroze TamboliFen WangEric Jonasch Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Nephrectomy | Renal Cell Carcinoma